Yahoo · Nov 13, 2026
Bear of the Day: Boston Scientific (BSX)
BSX growth continues to flatline but expects 2027 to mark cycle's trough, 2028 recovery driven by new launches

NYSE · BSX
Healthcare · Medical - Devices
$43.64
Down-$0.65 (-1.49%)
Updated Nov 20, 2026, 1:46 AM
SID Score
4.9/10
Composite research score
Smart Money
49/100
Neutral
Price performance · BSX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
BSX closed at $43.64 after 20 trading sessions, down 5.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $42.50 | $44.32 | $42.50 | $43.64 | 13.25M |
| Nov 17, 2026 | $43.28 | $43.825 | $43.015 | $43.03 | 12.91M |
| Nov 16, 2026 | $44.63 | $44.86 | $43.505 | $43.69 | 16.11M |
| Nov 13, 2026 | $44.69 | $44.69 | $44.08 | $44.34 | 9.7M |
| Nov 12, 2026 | $45.40 | $45.60 | $43.79 | $44.20 | 11.51M |
| Nov 11, 2026 | $44.06 | $45.8151 | $43.8692 | $45.13 | 17.79M |
| Nov 10, 2026 | $43.58 | $44.78 | $43.40 | $44.70 | 11.71M |
| Nov 9, 2026 | $43.35 | $44.33 | $43.04 | $44.02 | 16.2M |
| Nov 6, 2026 | $43.35 | $43.63 | $42.69 | $42.75 | 14.71M |
| Nov 5, 2026 | $46.585 | $46.85 | $43.895 | $44.64 | 22.49M |
| Nov 4, 2026 | $44.805 | $46.97 | $44.76 | $45.82 | 34.56M |
| Nov 3, 2026 | $43.87 | $44.615 | $43.21 | $43.50 | 18.89M |
| Nov 2, 2026 | $42.07 | $44.365 | $41.90 | $44.32 | 22.71M |
| Oct 30, 2026 | $42.95 | $43.29 | $41.725 | $41.98 | 22.47M |
| Oct 29, 2026 | $41.81 | $43.085 | $41.675 | $42.69 | 31.76M |
| Oct 28, 2026 | $41.95 | $43.915 | $39.57 | $42.43 | 69.84M |
| Oct 27, 2026 | $45.29 | $45.33 | $44.855 | $45.06 | 15.14M |
| Oct 26, 2026 | $45.31 | $46.07 | $45.125 | $45.58 | 11.93M |
| Oct 23, 2026 | $45.84 | $46.16 | $45.215 | $45.69 | 8.77M |
| Oct 22, 2026 | $44.72 | $46.05 | $44.62 | $46.01 | 16.4M |
The latest Smart Investors Daily articles mentioning BSX.
Company
Market Activity
Research & News
BSX research
Company profile and research snapshot.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | TD Cowen | Hold | — |
| Oct 30, 2026 | Barclays | Equal-Weight | — |
| Oct 29, 2026 | UBS | Buy | — |
| Oct 29, 2026 | Leerink Partners | Outperform | — |
| Oct 29, 2026 | Citigroup | Neutral | — |
No generated briefing is available yet.
Yahoo · Nov 13, 2026
BSX growth continues to flatline but expects 2027 to mark cycle's trough, 2028 recovery driven by new launches
Yahoo · Nov 12, 2026
Actionable insights reveal new revenue streams, growth opportunities, competitive strategies, and trends in minimally invasive, image-guided peripheral embolizationDublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "U.S. Peripheral Liquid Embolic Agents Market Size, Share & Trends Analysis Report 2026-2036" has been added to ResearchAndMarkets.com's offering. The U.S. peripheral liquid embolic agents market was valued at USD 99.7 million in 2025 and is projected to increase from USD 110.3 million in 2026
Yahoo · Nov 12, 2026
With Johnson & Johnson’s support, Francis plans to take its water-vapor therapy device through the premarket approval process.
Yahoo · Nov 12, 2026
Boston Scientific (BSX) is back in focus after a series of voluntary Class II recalls for its Direxion Torqueable Microcatheter lines, raising questions about quality control, regulatory exposure, and how much risk is now priced into the stock. Recent recall headlines have landed on a stock that was already under pressure. Boston Scientific’s share price is at US$45.13, with a year to date share price return down 52.35% and a 1 year total shareholder return down 56.66%. The 5 year total...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning BSX.